Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 1 2Phase NA 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 1Gastrointestinal 1

Conditions

Glioblastoma 60Carcinoma, Non-Small-Cell Lung 48Lung Neoplasms 39Head and Neck Neoplasms 26Gliosarcoma 26Squamous Cell Carcinoma of Head and Neck 25Pancreatic Neoplasms 25Central Nervous System Neoplasms 23Brain Neoplasms 22Rectal Neoplasms 21Breast Neoplasms 17Astrocytoma 17Sarcoma 16Neoplasms 16Glioma 15Uterine Cervical Neoplasms 14Prostatic Neoplasms 14Esophageal Neoplasms 14Carcinoma, Squamous Cell 11Lymphoma, Follicular 10Leukemia 10Melanoma 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma 9Leukemia, Lymphocytic, Chronic, B-Cell 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Non-Hodgkin 8Neoplasm Metastasis 7Myelodysplastic Syndromes 7Lymphoma, Mantle-Cell 7

Interventions

tremelimumab 2fludarabine 2durvalumab 2aflibercept 2Trastuzumab 2Radiotherapy 2Radiosurgery 2Cyclophosphamide 2Cisplatin 2tipifarnib 1sapropterin 1oncogene protein E7, Human papillomavirus type 16 1entinostat 1Vaccines 1Topotecan 1Therapeutics 1Radiation 1Platinum 1Pharmacogenomic Testing 1Papillomavirus Vaccines 1Nelfinavir 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunoglobulin G 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Gemcitabine 1Ganciclovir 1E6 protein, Human papillomavirus type 16 1Docetaxel 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Vulvar Neoplasms × Radiotherapy × Clear all
NCT03277482 2025-05-31

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Dana-Farber Cancer Institute

Phase 1 Terminated
16 enrolled
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT00003704 2016-07-06

Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer

Alliance for Clinical Trials in Oncology

Phase 1 Completed
51 enrolled
GastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Fallopian Tube Neoplasms, Neoplasms, Penile Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Testicular Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡